euglena Co., Ltd. (2931) AI Stock Analysis

• Market Cap: ¥56.41B
• Dividend Yield: N/A
• Average Volume (3M): 958.05K
• Price to Earnings (P/E): 3152.3
• Beta (1Y): 0.69
• Revenue Growth: 3.68%
• EPS Growth: N/A
• Country: JP
• Employees: 897
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 1.31
• Shares Outstanding: 136,599,260
• 10 Day Avg. Volume: 1,429,850
• 30 Day Avg. Volume: 958,053
• PEG Ratio: 1.09
• Price to Book (P/B): 1.76
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 29.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: ¥395.00 ▼(-2.95% Downside)

Euglena Co., Ltd. faces significant challenges with profitability and valuation, as indicated by a high P/E ratio and negative net profit margin. The stock's bearish technical indicators further weigh down its attractiveness. Despite improvements in revenue growth and cash flow, the company's financial performance is not strong enough to offset these concerns.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability.

Cash Flow Management

Improved cash flow management enhances liquidity, providing the company with greater financial flexibility for growth and investment.

Balance Sheet Health

A healthier balance sheet with a lower debt-to-equity ratio reduces financial risk and supports long-term stability.

Negative Factors

Profitability Challenges

Ongoing profitability issues hinder the company's ability to generate returns, impacting long-term financial health and shareholder value.

Return on Equity

Negative return on equity suggests inefficiencies in generating shareholder returns, posing a challenge for future growth and investment attraction.

Net Losses

Continued net losses indicate operational challenges that could limit reinvestment opportunities and long-term growth potential.

euglena Co., Ltd. Business Overview & Revenue Model

Company Description

Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae. It operates through Healthcare Business and Energy/Environment Business segments. The company also manufactures and sells foods and cosmetics using euglena. In addition, it offers health foods, beverages, confectionery, and sports food products. Further, the company develops biofuel technology and environmental related technology for microalgae; and invests in biotechnology related business. It distributes its products at convenience stores, drugstores, supermarkets, beauty salons, and variety shops. The company was incorporated in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Euglena Co., Ltd. generates revenue through multiple streams, primarily by selling dietary supplements and functional foods that incorporate Euglena as a key ingredient. The company has developed a range of products targeting health-conscious consumers, including capsules, powders, and fortified foods that emphasize the nutritional benefits of Euglena, such as its high protein and vitamin content. Additionally, Euglena Co., Ltd. earns income from its cosmetics division, where it offers skincare products utilizing the antioxidant properties of Euglena. The company may also engage in partnerships with other firms in the food, health, and beauty industries to expand its product offerings and market reach. Furthermore, the company invests in research and development to innovate new applications for Euglena and enhance its existing products, which can contribute to long-term revenue growth.

euglena Co., Ltd. Financial Statement Overview

Summary

Euglena Co., Ltd. shows positive revenue growth and improved cash flow management. However, profitability remains a concern with negative net profit and return on equity. The balance sheet is healthier with a lower debt-to-equity ratio, but further efforts are needed to enhance shareholder returns.

Income Statement

Euglena Co., Ltd. has shown a modest revenue growth rate of 2.44% in the latest year, indicating a positive trend in sales. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -1.37% and a low EBIT margin of 0.36%. The gross profit margin remains strong at 69.86%, suggesting efficient production processes. Despite improvements, the company needs to address its net losses to enhance overall financial health.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.82, indicating a more balanced capital structure compared to previous years. However, the return on equity remains negative at -2.05%, reflecting ongoing challenges in generating returns for shareholders. The equity ratio stands at 43.28%, which is a positive indicator of financial stability. Continued focus on reducing debt and improving profitability is essential for long-term growth.

Cash Flow

Euglena Co., Ltd. has demonstrated a significant improvement in free cash flow growth, with a 55.66% increase, highlighting better cash management. The operating cash flow to net income ratio of 0.21 indicates that the company is generating cash from operations, albeit at a moderate level. The free cash flow to net income ratio of 0.72 suggests that the company is effectively converting its earnings into cash, which is a positive sign for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.88B	47.62B	46.48B	44.39B	23.29B	13.32B
Gross Profit	34.18B	33.27B	31.77B	31.00B	15.00B	9.49B
EBITDA	5.21B	3.77B	1.34B	676.00M	-2.23B	-717.06M
Net Income	-352.50M	-650.00M	-2.65B	-2.68B	-3.23B	-1.49B
Balance Sheet
Total Assets	69.09B	73.26B	59.62B	57.27B	64.07B	15.35B
Cash, Cash Equivalents and Short-Term Investments	18.54B	20.63B	15.79B	9.95B	11.30B	6.25B
Total Debt	22.66B	25.92B	25.07B	22.22B	25.79B	3.76B
Total Liabilities	37.39B	41.14B	39.41B	37.92B	41.88B	5.96B
Stockholders Equity	30.59B	31.70B	20.21B	19.35B	22.19B	9.38B
Cash Flow
Free Cash Flow	2.41B	1.91B	-35.00M	428.00M	1.17B	-1.61B
Operating Cash Flow	2.66B	2.65B	658.00M	924.00M	1.50B	-1.22B
Investing Cash Flow	-7.63B	-7.99B	-646.00M	1.23B	-10.21B	-350.53M
Financing Cash Flow	-992.00M	-485.00M	5.83B	-2.99B	12.99B	162.89M

euglena Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 407.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Neutral. The current price of 407 is above the 20-day moving average (MA) of 402.10, below the 50-day MA of 408.72, and below the 200-day MA of 438.08, indicating a neutral trend. The MACD of -0.98 indicates Negative momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2931.

euglena Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4928	76 Outperform	¥159.34B	19.84	―	5.00%	1.41%	0.75%
4923	66 Neutral	¥34.14B	24.48	―	1.81%	0.22%	4.15%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2931	48 Neutral	¥56.41B	3,152.34	―	―	3.68%	―

euglena Co., Ltd. Corporate Events

Euglena Co., Ltd. Reports Financial Results with Positive Sales Growth

Euglena Co., Ltd. reported its consolidated financial results for the nine months ending September 30, 2025, showing a 5.1% increase in net sales to ¥37,086 million and a significant rise in adjusted EBITDA by 68.1% to ¥5,457 million. Despite these positive indicators, the company recorded a loss of ¥380 million attributable to the owners of the parent, although this is an improvement from the previous year’s loss of ¥1,048 million. The company’s financial position remains stable with a slight increase in the equity-to-asset ratio, and it has revised its earnings forecast for the fiscal year ending December 31, 2025, indicating a positive outlook with expected net sales of ¥50,000 million.

The most recent analyst rating on (JP:2931) stock is a Hold with a Yen461.00 price target. To see the full list of analyst forecasts on euglena Co., Ltd. stock, see the JP:2931 Stock Forecast page.

Euglena Co., Ltd. Reports Strong Q3 FY2025 Growth, Revises Forecast Upwards

Euglena Co., Ltd. has reported a significant increase in its financial performance for Q3 FY2025, driven primarily by growth in its healthcare business. The company’s sales and operating profit have seen substantial year-on-year increases, with adjusted EBITDA rising by 68% and operating profit multiplying sixteenfold. This growth is attributed to the consolidation of Saticine Medical, organic growth in direct sales, and company-wide profitability initiatives. Despite the healthcare sector’s progress exceeding expectations, the biofuel segment lagged slightly behind. The company has revised its full-year forecast upwards for adjusted EBITDA and operating profit, anticipating record levels, while maintaining its revenue forecast.

The most recent analyst rating on (JP:2931) stock is a Hold with a Yen461.00 price target. To see the full list of analyst forecasts on euglena Co., Ltd. stock, see the JP:2931 Stock Forecast page.